摘要:
Compounds of the formula are disclosed as Mnk2 inhibitors which are useful for the treatment and prevention of metabolic disorders such as obesity and diabetes.
摘要:
N-heterocyclic compounds that block cytokine production via inhibition of p38 kinase are disclosed. In one embodiment, compounds of the present invention are represented by Formula (I): Methods of production, pharmaceutical compositions and methods of treating conditions associated with inappropriate p38 kinase activity or TNF-α expression utilizing compounds of the present invention are also disclosed.
摘要:
A chemical genus of purinones and 1H-imidazopyridinones, which are useful as PKCθ. inhibitors, and their methods of use are disclosed. The genus is represented by the formula I: wherein R1 is chosen from nitrogen-attached heterocyclyl, nitrogen-attached substituted heterocyclyl wherein the point of attachment is a nitrogen heteroatom, and R2 is chosen from aryl, substituted aryl, arylalkyl, substituted arylalkyl, heteroaryl, substituted heteroaryl, hetroarylalkyl, and substituted heteroarylalkyl. A representative example is:
摘要:
A chemical genus of purinones and 1H-imidazopyridinones, which are useful as PKCθ inhibitors, and their methods of use are disclosed. The genus is represented by the formula I:
摘要:
The present invention provides novel purinones and purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulae I and II shown below, in which Q is selected from the group consisting of CX and nitrogen; and A is chosen from the group consisting of H, (C1-C6) alkyl, heteroaryl, and aryl:
摘要:
A chemical genus of purinones and 1H-imidazopyridinones, which are useful as PKCθ inhibitors, and their methods of use are disclosed. The genus is represented by the formula I: A representative example is:
摘要:
Disclosed herein are various embodiments of methods and systems for determining the orientation and direction of first motion of a fault or fracture by optimizing an azimuthally-dependent attribute of signals generated by microseismic sources, comprising: recording microseismic data traces using a of sensors located at a plurality of sensor positions; subdividing the subsurface volume into spatial volumes corresponding to selected time intervals and comprising a plurality of voxels; for each voxel, applying a time shift to the microseismic data traces that is substantially equal to a travel time from each voxel to the corresponding sensor position, and determining for the voxel the orientation and direction of first motion of the fault or fracture corresponding to a maximum value for the voxel of at least one azimuthally-dependent attribute of the microseismic data traces.
摘要:
Disclosed herein are various embodiments of methods and systems for determining the orientation and direction of first motion of a fault or fracture by optimizing an azimuthally-dependent attribute of signals generated by microseismic sources, comprising: recording microseismic data traces using a of sensors located at a plurality of sensor positions; subdividing the subsurface volume into spatial volumes corresponding to selected time intervals and comprising a plurality of voxels; for each voxel, applying a time shift to the microseismic data traces that is substantially equal to a travel time from each voxel to the corresponding sensor position, and determining for the voxel the orientation and direction of first motion of the fault or fracture corresponding to a maximum value for the voxel of at least one azimuthally-dependent attribute of the microseismic data traces.
摘要:
The present invention provides novel purinones and purines useful for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection. The compounds are of the general formulae I and II:
摘要:
The present invention relates to a pyrrolo[2,3-d]pyrimidin-2-yl-amine derivative according to formula (I) wherein the variables are defined as in the specification, or to a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to a pharmaceutical composition comprising one or more of said pyrrolo[2,3-d]pyrimidine-2-ylamine derivatives and to their use in therapy, for instance in the treatment of PKCθ mediated disorders.